Part One: Molecular Screening and Treatment in MDS, Mutant IDH as a Target, and Enasidenib
Part Two: Luspatercept in Lower Risk MDS: Updates from the PACE Study and Phase 2 Studies in Patients with Anemia

Download Transcript Download Audio

MediCom Worldwide, Inc. Links

ManagingAML.com | ManagingMyeloma.com | ManagingMPN.com | ManagingLymphoma.com | PracticalOncologist.com | PracticalHematologist.com | ManagingCVD.com | ManagingSCD.com | MediComWorldwide.com